The Presence of Lung Cancer Affects SARS-CoV-2 Vaccine Uptake and Attitude in Chinese Patients: A Clinical Cross-Sectional Investigation

Abstract

With the SARS-CoV-2 mutations evolving and prompt of SARS-CoV-2 vaccines, no information is available on SARS-CoV-2 vaccination status in Chinese patients with lung cancer. An electronic questionnaire including sociodemographic characteristics, vaccine status, side effect post-vaccination, and attitude towards a fourth dose of vaccine was conducted within 1018 Chinese patients with lung cancer from October 18th, 2022, to November 25th, 2022. Among 1018 patients, a total of 75 (13.7%) patients reported acceptable systemic adverse events in those had received the SARS-CoV-2 vaccine (549, 54%), the most common of which was fever (39, 7%). Factors including females (OR, 1.512; 95% CI, 1.076–2.124), residents in the municipality (OR, 2.048; 95% CI, 1.238–3.389), undergoing therapy (OR, 2.897; 95% CI, 1.348–6.226), disagree to vaccines is safe for patients with lung cancer (OR, 3.816; 95% CI, 2.198–6.626) contributed to hesitancy. Among 373 patients had received three doses, half respondents (206, 55.2%) were hesitant to receive a fourth dose due to the safety concern and efficacy towards the variants. In conclusion, low vaccine uptake rates in patients with lung cancer could be improved by increasing confidence in vaccine safety, particularly for those with negative beliefs. Appropriate guidance and individualized vaccination plans that meet the healthcare needs of patients with lung cancer were needed during the constantly evolving pandemic.

Keywords:

• SARS-CoV-2 Vaccine
• lung cancer
• vaccine uptake
• adverse events
• vaccine hesitancy

Acknowledgments

We acknowledge all the patients and their family members for participating in the questionnaire. We acknowledge the doctors and nurses from hospitals of CAPTRA-Lung collaboration for questionnaire collection. The hospitals encompassed in CAPTRA-Lung collaboration, including:

1. Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, P. R. China;

2. Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, 100142, P. R. China;

3. Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China;

4. Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, P. R. China;

5. Department of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing, 100044, P. R. China;

6. Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, P. R. China;

7. Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, 101125, P. R. China;

8. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610000, P. R. China.

9. Department of Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610000, P. R. China;

10. Respiratory medicine, Shanxi Cancer Hospital, Taiyuan, Shanxi, 030013, P. R. China;

11. Department of Oncology, Shanxi Bethune Hospital, Taiyuan, Shanxi, 030032, P. R. China;

12. Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin, 301699, P. R. China;

13. Department of Lung Cancer Surgery. Tianjin Medical University General Hospital, Tianjin, 300052, P. R. China;

14. Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China;

15. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, P. R. China;

16. Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, 150086, P. R. China;

17. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, 150081, P. R. China;

18. Department of Oncology, Heilongjiang Second Cancer Hospital, Haerbin, Heilongjiang, 150088, P. R. China;

19. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110002, P. R. China;

20. Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, P. R. China;

21. Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, 050199, P. R. China;

22. Department of Oncology, Inner Mongolia Autonomous Region People’s Hospital, Hohhot, Inner Mongolia Autonomous Region, 750306, P. R. China;

23. Department of Respiratory Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 750306, P. R. China;

24. Department of Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia Autonomous Region, 014030, P. R. China;

25. Department of Oncology, The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia Autonomous Region, 014017, P. R. China

26. Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha, Changsha, Hunan, 410005, P. R. China;

27. Department of Respiratory and Critical Care Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, P. R. China;

28. Department of Respiratory and Critical Care Medicine, Changzhi People’s Hospital, Changzhi, Shanxi, 046099, P. R. China;

29. Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330008, P. R. China;

30. Department of Oncology, Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, 130061, P. R. China;

31. Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, 250063, P. R. China;

32. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, P. R. China;

33. Department of Oncology, The First Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang, 832099, P. R. China.

34. Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Beijing, 100020, P. R. China;

35. Department of Oncology, Beijing Shijitan Hospital, Beijing, 100038, P. R. China;

36. Department of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, 100005, P. R. China;

37. Department of Oncology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, 310006, P. R. China.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data presented in the study can be directed to the corresponding authors.

Additional information

Funding

This work was supported by Beijing Natural Science Foundation (L222070).